Sign Up Today and Learn More About F2G Stock
Invest in or calculate the value of your shares in F2G or other pre-IPO companies through EquityZen's platform.
F2G Stock (FTWG)
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
About F2G Stock
Founded
1998
Industries
Science and Engineering, Health Care, Biotechnology
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
F2G Press Mentions
Stay in the know about the latest news on F2G
F2G seeks second bite of the cherry with $100 million round as novel antifungal pipeline remains thin
thepharmaletter • Jan 10, 2025
F2G Announces $100 Million Financing to Advance Late-Stage
globenewswire • Jan 10, 2025
Antibiotics and Antimycotics Market Size to Hit $91.54 Billion, Globally at 5.2% CAGR by 2031 - Exclusive Report by The Insight Partners
globenewswire • Nov 29, 2024
Armed with $100m funding, F2G prepares to refile antifungal
pharmaphorum • Sep 18, 2024
ANTIMYKHTIASIKO MEDICINAL PREPARATION
patents • Apr 14, 2024
F2G Management
Leadership team at F2G
Chief Executive Officer
Ian Nicholson
Chief Scientific and Development Officer
Tony Kennedy
Join now and verify your accreditation status to gain access to:
- F2G Current Valuation
- F2G Stock Price
- F2G Management
- Available deals in F2G and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- F2G Cap Table and Funding History by Share Class and Liquidity Preferences
- F2G Revenue and Financials
- F2G Highlights
- F2G Business Model
- F2G Risk Factors
- F2G Research Report from SACRA Research
Trading F2G Stock
How to invest in F2G stock?
Accredited investors can buy pre-IPO stock in companies like F2G through EquityZen funds. These investments are made available by existing F2G shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell F2G stock?
Shareholders can sell their F2G stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
